LRRK2 kinase inhibition reverses G2019S mutation-dependent effects on tau pathology progression.

Noah LubbenJulia K BrynildsenConnor M WebbHoward L LiCheryl E G LeynsLakshmi ChangolkarBin ZhangEmily S MeymandMia O'ReillyZach MadajDaniella DeWeerdMatthew J FellVirginia M Y LeeDani S BassettMichael X Henderson

Published in: Translational neurodegeneration (2024)

This work supports a protective role of LRRK2 kinase inhibition in G2019S carriers and provides a rational workflow for systematic evaluation of brain-wide phenotypes in therapeutic development.

Keyphrases

protein kinase
tyrosine kinase
resting state
cerebrospinal fluid
functional connectivity